

- Oritavancin is a semisynthetic lipoglycopeptide approved for acute bacterial skin and skin structure infections (ABSSSI).
- Oritavancin has a unique mechanism of action with activity against methicillin-resistant *Staphylococcus aureus* and both VanA and VanB mediated vancomycin-resistant enterococci.
- Owing to its improved activity and prolonged half-life, it is administered as a single intravenous dose for ABSSSI.
- This review focuses on the spectrum of activity, mechanisms of action, resistance pharmacodynamic and pharmacokinetic properties as well as the current and ongoing clinical studies.

This summary slide represents the opinions of the authors. No sponsorship or funding was received for this publication. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).